文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

新辅助未治疗食管癌患者的组织学预后指标

Histological prognosticators in neoadjuvant naive oesophageal cancer patients.

作者信息

Hardy Kiera, Chmelo Jakub, Joel Abraham, Navidi Maziar, Fergie Bridget H, Phillips Alexander W

机构信息

Northern Oesophagogastric Unit, Royal Victoria Infirmary, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.

Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.

出版信息

Langenbecks Arch Surg. 2023 May 9;408(1):184. doi: 10.1007/s00423-023-02927-z.


DOI:10.1007/s00423-023-02927-z
PMID:37156834
Abstract

PURPOSE: Prognosis of oesophageal cancer is primarily based upon the TNM stage of the disease. However, even in those with similar TNM staging, survival can be varied. Additional histopathological factors including venous invasion (VI), lymphatic invasion (LI) and perineural invasion (PNI) have been identified as prognostic markers yet are not part of TNM classification. The aim of this study is to determine the prognostic importance of these factors and overall survival in patients with oesophageal or junctional cancer who underwent transthoracic oesophagectomy as the unimodality treatment. METHODS: Data from patients who underwent transthoracic oesophagectomy for adenocarcinoma without neoadjuvant treatment were reviewed. Patients were treated with radical resection, with a curative intent using a transthoracic Ivor Lewis or three staged McKeown approach. RESULTS: A total of 172 patients were included. Survival was poorer when VI, LI and PNI were present (p<0.001), with the estimated survival being significantly worse (p<0.001) when patients were stratified according to the number of factors present. Univariable analysis of factors revealed VI, LI and PNI were all associated with survival. Presence of LI was independently predictive of incorrect staging/upstaging in multivariable logistic regression analysis (OR 12.9 95% CI 3.6-46.6, p<0.001). CONCLUSION: Histological factors of VI, LI and PNI are markers of aggressive disease and may have a role in prognostication and decision-making prior to treatment. The presence of LI as an independent marker of upstaging could be a potential indication for the use of neoadjuvant treatment in patients with early clinical disease.

摘要

目的:食管癌的预后主要基于疾病的TNM分期。然而,即使在TNM分期相似的患者中,生存率也可能有所不同。其他组织病理学因素,包括静脉侵犯(VI)、淋巴侵犯(LI)和神经周围侵犯(PNI),已被确定为预后标志物,但并非TNM分类的一部分。本研究的目的是确定这些因素以及接受经胸食管切除术作为单一治疗方式的食管或交界性癌患者的总生存率的预后重要性。 方法:回顾了接受经胸食管切除术治疗腺癌且未接受新辅助治疗的患者的数据。患者接受根治性切除,采用经胸Ivor Lewis或三阶段McKeown方法,以达到治愈目的。 结果:共纳入172例患者。存在VI、LI和PNI时生存率较差(p<0.001),根据存在的因素数量对患者进行分层时,估计生存率明显更差(p<0.001)。对因素的单变量分析显示,VI、LI和PNI均与生存率相关。在多变量逻辑回归分析中,LI的存在独立预测分期错误/分期上调(OR 12.9,95%CI 3.6 - 46.6,p<0.001)。 结论:VI、LI和PNI的组织学因素是侵袭性疾病的标志物,可能在预后评估和治疗前的决策中发挥作用。LI作为分期上调的独立标志物的存在可能是早期临床疾病患者使用新辅助治疗的潜在指征。

相似文献

[1]
Histological prognosticators in neoadjuvant naive oesophageal cancer patients.

Langenbecks Arch Surg. 2023-5-9

[2]
The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence.

Br J Cancer. 2015-11-17

[3]
Prognostic Significance of Lymphatic, Venous and Perineural Invasion After Neoadjuvant Chemotherapy in Patients with Gastric Adenocarcinoma.

Ann Surg Oncol. 2020-9

[4]
Impact of perineural invasion as a histopathological prognostic factor in ypStage II/III oesophageal squamous cell carcinoma†.

Eur J Cardiothorac Surg. 2019-5-1

[5]
Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.

World J Gastroenterol. 2018-4-7

[6]
The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma.

World J Surg Oncol. 2022-1-10

[7]
Perineural invasion through the sheath in posttherapy esophagectomy specimens predicts poor survival in patients with esophageal squamous cell carcinoma.

Eur J Surg Oncol. 2017-10

[8]
Perineural invasion predicts for locoregional failure in patients with oesophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy.

J Clin Pathol. 2021-4

[9]
Effectiveness and safety of minimally invasive Ivor Lewis and McKeown oesophagectomy in Chinese patients with stage IA-IIIB oesophageal squamous cell cancer: a multicentre, non-interventional and observational study.

Interact Cardiovasc Thorac Surg. 2020-6-1

[10]
Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.

BMC Cancer. 2017-1-19

本文引用的文献

[1]
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

N Engl J Med. 2021-4-1

[2]
Three decades of oesophagogastric cancer care: now a curable disease.

Br J Surg. 2021-6-22

[3]
Staging esophageal cancer: low EUS accuracy in t2n0 patients.

Endosc Int Open. 2021-3

[4]
Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling.

Ann Oncol. 2021-4

[5]
Adverse Biology in Adenocarcinoma of the Esophagus and Esophagogastric Junction Impacts Survival and Response to Neoadjuvant Therapy Independent of Anatomic Subtype.

Ann Surg. 2020-11

[6]
Prognostic Significance of Lymphatic, Venous and Perineural Invasion After Neoadjuvant Chemotherapy in Patients with Gastric Adenocarcinoma.

Ann Surg Oncol. 2020-9

[7]
Management of clinical T2N0 esophageal cancer: a review.

J Thorac Dis. 2019-8

[8]
Prognostic value of lymphovascular invasion in patients with esophageal squamous cell carcinoma.

Ann Transl Med. 2019-6

[9]
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Lancet. 2019-4-11

[10]
Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options.

Int J Surg. 2018-5-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索